Breaking News

Questcor To Acquire BioVectra

Gains API manufacturing capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Questcor Pharmaceuticals has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of $50.6 million. BioVectra provides contract manufacturing services to the global pharmaceutical and biotechnology industry, and manufactures APIs, chemical intermediates, and bioprocessing reagents.   BioVectra has been Questcor’s manufacturing partner for the API in Questcor’s H.P. Acthar Gel (repository corticotropin injection) for the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters